HRP20110161T1 - 18-metil-19-nor-androst-4-en-17,17-spiroeter (18-metil-19-nor-20-spiroks-4-en-3-oni) i farmaceutski pripravci koji ih sadrže - Google Patents

18-metil-19-nor-androst-4-en-17,17-spiroeter (18-metil-19-nor-20-spiroks-4-en-3-oni) i farmaceutski pripravci koji ih sadrže Download PDF

Info

Publication number
HRP20110161T1
HRP20110161T1 HR20110161T HRP20110161T HRP20110161T1 HR P20110161 T1 HRP20110161 T1 HR P20110161T1 HR 20110161 T HR20110161 T HR 20110161T HR P20110161 T HRP20110161 T HR P20110161T HR P20110161 T1 HRP20110161 T1 HR P20110161T1
Authority
HR
Croatia
Prior art keywords
spirox
methyl
methylene
group
pharmaceutical preparations
Prior art date
Application number
HR20110161T
Other languages
English (en)
Croatian (hr)
Inventor
Bohlmann Rolf
Kuhnke Joachim
H�bner Jan
Gallus Norbert
Menges Frederik
Borden Steffen
Muhn Hans-Peter
Prelle Katja
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110161(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20110161T1 publication Critical patent/HRP20110161T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0083 membered carbocyclic rings in position 15/16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
HR20110161T 2006-06-29 2011-03-04 18-metil-19-nor-androst-4-en-17,17-spiroeter (18-metil-19-nor-20-spiroks-4-en-3-oni) i farmaceutski pripravci koji ih sadrže HRP20110161T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
PCT/EP2007/005893 WO2008000521A1 (de) 2006-06-29 2007-06-29 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate

Publications (1)

Publication Number Publication Date
HRP20110161T1 true HRP20110161T1 (hr) 2011-04-30

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110161T HRP20110161T1 (hr) 2006-06-29 2011-03-04 18-metil-19-nor-androst-4-en-17,17-spiroeter (18-metil-19-nor-20-spiroks-4-en-3-oni) i farmaceutski pripravci koji ih sadrže

Country Status (41)

Country Link
US (1) US7846917B2 (sl)
EP (1) EP2038294B1 (sl)
JP (1) JP5326085B2 (sl)
KR (1) KR101440640B1 (sl)
CN (1) CN101511857B (sl)
AR (1) AR061736A1 (sl)
AT (1) ATE490967T1 (sl)
AU (1) AU2007263944B2 (sl)
BR (1) BRPI0713934A2 (sl)
CA (1) CA2656443C (sl)
CL (1) CL2007001919A1 (sl)
CO (1) CO6150134A2 (sl)
CR (1) CR10548A (sl)
CY (1) CY1111658T1 (sl)
DE (2) DE102006030416A1 (sl)
DK (1) DK2038294T3 (sl)
DO (1) DOP2008000089A (sl)
EC (1) ECSP089014A (sl)
ES (1) ES2357698T3 (sl)
GT (1) GT200800307A (sl)
HK (1) HK1133659A1 (sl)
HN (1) HN2008001934A (sl)
HR (1) HRP20110161T1 (sl)
IL (1) IL195935A0 (sl)
MA (1) MA30596B1 (sl)
MX (1) MX2009000082A (sl)
MY (1) MY155015A (sl)
NO (1) NO20090459L (sl)
NZ (1) NZ573951A (sl)
PE (1) PE20080995A1 (sl)
PL (1) PL2038294T3 (sl)
PT (1) PT2038294E (sl)
RS (1) RS51722B (sl)
RU (1) RU2440365C2 (sl)
SI (1) SI2038294T1 (sl)
TN (1) TNSN08518A1 (sl)
TW (1) TWI413645B (sl)
UA (1) UA94952C2 (sl)
UY (1) UY30451A1 (sl)
WO (1) WO2008000521A1 (sl)
ZA (1) ZA200900673B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) 2012-04-23 2013-12-16 Bayer Pharma AG 18-甲基-15β,16β-亞甲基-19-降-20-螺氧-4-烯-3-酮的子宮內用途,包含18-甲基-15β,16β-亞甲基-19-降-20-螺氧-4-烯-3-酮的子宮內系統,及其於避孕及婦科治療之用途
SG11201406583QA (en) * 2012-04-23 2014-11-27 Bayer Pharma AG Application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spi
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
WO2015055635A1 (en) * 2013-10-18 2015-04-23 Bayer Oy Intrauterine delivery system
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) * 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1223174A3 (en) 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

Also Published As

Publication number Publication date
CN101511857B (zh) 2012-10-31
RS51722B (en) 2011-10-31
NZ573951A (en) 2011-06-30
PT2038294E (pt) 2011-03-14
ECSP089014A (es) 2009-01-30
PL2038294T3 (pl) 2011-05-31
AU2007263944B2 (en) 2013-07-18
HK1133659A1 (sl) 2010-04-01
MA30596B1 (fr) 2009-07-01
CN101511857A (zh) 2009-08-19
CO6150134A2 (es) 2010-04-20
TWI413645B (zh) 2013-11-01
US20080153787A1 (en) 2008-06-26
RU2009102772A (ru) 2010-08-10
AR061736A1 (es) 2008-09-17
EP2038294B1 (de) 2010-12-08
BRPI0713934A2 (pt) 2012-12-04
ZA200900673B (en) 2010-04-28
PE20080995A1 (es) 2008-10-03
CY1111658T1 (el) 2015-10-07
NO20090459L (no) 2009-03-10
DE102006030416A1 (de) 2008-01-03
RU2440365C2 (ru) 2012-01-20
CR10548A (es) 2009-01-27
JP2009541405A (ja) 2009-11-26
KR101440640B1 (ko) 2014-09-22
SI2038294T1 (sl) 2011-04-29
CA2656443C (en) 2014-10-07
AU2007263944A1 (en) 2008-01-03
MX2009000082A (es) 2009-01-23
WO2008000521A1 (de) 2008-01-03
JP5326085B2 (ja) 2013-10-30
UY30451A1 (es) 2008-01-31
MY155015A (en) 2015-08-28
CA2656443A1 (en) 2008-01-03
GT200800307A (es) 2009-11-03
KR20090021294A (ko) 2009-03-02
TW200811193A (en) 2008-03-01
TNSN08518A1 (en) 2010-04-14
UA94952C2 (uk) 2011-06-25
EP2038294A1 (de) 2009-03-25
DK2038294T3 (da) 2011-03-28
DE502007005902D1 (de) 2011-01-20
HN2008001934A (es) 2012-01-17
US7846917B2 (en) 2010-12-07
IL195935A0 (en) 2009-09-01
ATE490967T1 (de) 2010-12-15
CL2007001919A1 (es) 2008-05-16
DOP2008000089A (es) 2009-02-15
ES2357698T3 (es) 2011-04-28

Similar Documents

Publication Publication Date Title
HRP20110161T1 (hr) 18-metil-19-nor-androst-4-en-17,17-spiroeter (18-metil-19-nor-20-spiroks-4-en-3-oni) i farmaceutski pripravci koji ih sadrže
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
PL1888080T3 (pl) Kompozycje farmaceutyczne neuroaktywnego steroidu i jego zastosowanie
TW200605880A (en) Progesterone receptor antagonist contraceptive regimens and kits
DK1828222T3 (da) Fremgangsmåde til fremstilling af drospirenon
CA2594171A1 (en) 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
BRPI0713565A2 (pt) composição farmacêutica contendo ácido tetrahidrofólico
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
NZ609420A (en) Fulvestrant compositions and methods of use
CR20110519A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad glucocorticoide
RS51434B (en) MULTIPHASE NATURAL ESTOGENE-BASED CONTRACEPTION
AR049547A1 (es) Profarmacos de esteroides con accion androgenica
EP1599201A4 (en) SELECTIVE MODULATORS OF NON-STEROIDAL GLUCOCORTICOID RECEPTORS
GB0202635D0 (en) Formulation containing novel anti-inflammatory androstane derivative
CA2229960A1 (en) Steroid compounds having contraceptive and anti-osteoporosis activity
WO2003079965A3 (en) Derivatives of isoflavones
NO20072893L (no) Fast, peroralt prevensjonsmiddel
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
HRP20120952T1 (hr) 8-beta-supstituirani 16alfa-fluoro-estratrieni kao selektivno aktivni estrogeni
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest